Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine : In vitro Activity Against SARS-CoV-2 and Potential Mechanisms
SARS-CoV-2 is a newly identified virus that has resulted in over 1.3 M deaths globally and over 59 M cases globally to date. Small molecule inhibitors that reverse disease severity have proven difficult to discover. One of the key approaches that has been widely applied in an effort to speed up the translation of drugs is drug repurposing. A few drugs have shown in vitro activity against Ebola virus and demonstrated activity against SARS-CoV-2 in vivo . Most notably the RNA polymerase targeting remdesivir demonstrated activity in vitro and efficacy in the early stage of the disease in humans. Testing other small molecule drugs that are active against Ebola virus would seem a reasonable strategy to evaluate their potential for SARS-CoV-2. We have previously repurposed pyronaridine, tilorone and quinacrine (from malaria, influenza, and antiprotozoal uses, respectively) as inhibitors of Ebola and Marburg virus in vitro in HeLa cells and of mouse adapted Ebola virus in mouse in vivo . We have now tested these three drugs in various cell lines (VeroE6, Vero76, Caco-2, Calu-3, A549-ACE2, HUH-7 and monocytes) infected with SARS-CoV-2 as well as other viruses (including MHV and HCoV 229E). The compilation of these results indicated considerable variability in antiviral activity observed across cell lines. We found that tilorone and pyronaridine inhibited the virus replication in A549-ACE2 cells with IC 50 values of 180 nM and IC 50 198 nM, respectively. We have also tested them in a pseudovirus assay and used microscale thermophoresis to test the binding of these molecules to the spike protein. They bind to spike RBD protein with K d values of 339 nM and 647 nM, respectively. Human C max for pyronaridine and quinacrine is greater than the IC 50 hence justifying in vivo evaluation. We also provide novel insights into their mechanism which is likely lysosomotropic.
| Errataetall: |
UpdateIn: ACS Omega. 2021 Mar 10;6(11):7454-7468. - PMID 33778258 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2020) vom: 02. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Puhl, Ana C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 10.11.2023 published: Electronic UpdateIn: ACS Omega. 2021 Mar 10;6(11):7454-7468. - PMID 33778258 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.12.01.407361 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318653990 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318653990 | ||
| 003 | DE-627 | ||
| 005 | 20231225165813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.12.01.407361 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1062.xml |
| 035 | |a (DE-627)NLM318653990 | ||
| 035 | |a (NLM)33299990 | ||
| 035 | |a (PII)2020.12.01.407361 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Puhl, Ana C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine |b In vitro Activity Against SARS-CoV-2 and Potential Mechanisms |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: ACS Omega. 2021 Mar 10;6(11):7454-7468. - PMID 33778258 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a SARS-CoV-2 is a newly identified virus that has resulted in over 1.3 M deaths globally and over 59 M cases globally to date. Small molecule inhibitors that reverse disease severity have proven difficult to discover. One of the key approaches that has been widely applied in an effort to speed up the translation of drugs is drug repurposing. A few drugs have shown in vitro activity against Ebola virus and demonstrated activity against SARS-CoV-2 in vivo . Most notably the RNA polymerase targeting remdesivir demonstrated activity in vitro and efficacy in the early stage of the disease in humans. Testing other small molecule drugs that are active against Ebola virus would seem a reasonable strategy to evaluate their potential for SARS-CoV-2. We have previously repurposed pyronaridine, tilorone and quinacrine (from malaria, influenza, and antiprotozoal uses, respectively) as inhibitors of Ebola and Marburg virus in vitro in HeLa cells and of mouse adapted Ebola virus in mouse in vivo . We have now tested these three drugs in various cell lines (VeroE6, Vero76, Caco-2, Calu-3, A549-ACE2, HUH-7 and monocytes) infected with SARS-CoV-2 as well as other viruses (including MHV and HCoV 229E). The compilation of these results indicated considerable variability in antiviral activity observed across cell lines. We found that tilorone and pyronaridine inhibited the virus replication in A549-ACE2 cells with IC 50 values of 180 nM and IC 50 198 nM, respectively. We have also tested them in a pseudovirus assay and used microscale thermophoresis to test the binding of these molecules to the spike protein. They bind to spike RBD protein with K d values of 339 nM and 647 nM, respectively. Human C max for pyronaridine and quinacrine is greater than the IC 50 hence justifying in vivo evaluation. We also provide novel insights into their mechanism which is likely lysosomotropic | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Fritch, Ethan James |e verfasserin |4 aut | |
| 700 | 1 | |a Lane, Thomas R |e verfasserin |4 aut | |
| 700 | 1 | |a Tse, Longping V |e verfasserin |4 aut | |
| 700 | 1 | |a Yount, Boyd L |e verfasserin |4 aut | |
| 700 | 1 | |a Sacramento, Carol Queiroz |e verfasserin |4 aut | |
| 700 | 1 | |a Tavella, Tatyana Almeida |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Fabio Trindade Maranhão |e verfasserin |4 aut | |
| 700 | 1 | |a Weston, Stuart |e verfasserin |4 aut | |
| 700 | 1 | |a Logue, James |e verfasserin |4 aut | |
| 700 | 1 | |a Frieman, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Premkumar, Lakshmanane |e verfasserin |4 aut | |
| 700 | 1 | |a Pearce, Kenneth H |e verfasserin |4 aut | |
| 700 | 1 | |a Hurst, Brett L |e verfasserin |4 aut | |
| 700 | 1 | |a Andrade, Carolina Horta |e verfasserin |4 aut | |
| 700 | 1 | |a Levi, James A |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Nicole J |e verfasserin |4 aut | |
| 700 | 1 | |a Kisthardt, Samantha C |e verfasserin |4 aut | |
| 700 | 1 | |a Scholle, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Souza, Thiago Moreno L |e verfasserin |4 aut | |
| 700 | 1 | |a Moorman, Nathaniel John |e verfasserin |4 aut | |
| 700 | 1 | |a Baric, Ralph S |e verfasserin |4 aut | |
| 700 | 1 | |a Madrid, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Ekins, Sean |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2020) vom: 02. Dez. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:02 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.12.01.407361 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 02 |c 12 | ||